
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
A live webcast of the fireside chat can be accessed on the Investors section of the Abeona website under 'Events' at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 30 days.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company's fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company's development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona's novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN™, Abeona Assist™, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements Investor and Media Contact: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics [email protected]
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
a minute ago
- Business Wire
Rosen Law Firm Urges RxSight, Inc. (NASDAQ: RXST) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025. RxSight describes itself as a 'commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses.' For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that RxSight, Inc. (NASDAQ: RXST) Misled Investors Regarding its Business Operations. According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) RxSight was experiencing 'adoption challenges' and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) as a result of the foregoing, defendants' positive statements about RxSight's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against RxSight, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 22, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.


Hamilton Spectator
16 minutes ago
- Hamilton Spectator
S&P/TSX composite up Wednesday morning, U.S. markets also higher
TORONTO - Gains in battery metal stocks helped lift Canada's main stock index in late-morning trading on Wednesday, while U.S. markets also rose. The S&P/TSX composite index was up 76.52 points at 27,440.95. In New York, the Dow Jones industrial average was up 204.92 points at 44,707.36. The S&P 500 index was up 15.51 points at 6,325.13, while the Nasdaq composite was up 13.96 points at 20,906.65. The Canadian dollar traded for 73.45 cents US compared with 73.34 cents US on Tuesday. The September crude oil contract was down 44 cents US at US$64.87 per barrel. The August gold contract was down US$20.60 at US$3,423.10 an ounce. This report by The Canadian Press was first published July 23, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD)
Yahoo
30 minutes ago
- Yahoo
Texas Instruments Stock Nosedives After Shock Earnings Outlook
July 23 - Texas Instruments (NASDAQ:TXN) shares fell more than 10% in pre-market trading Wednesday after its third-quarter revenue outlook came in below Wall Street estimates, despite delivering stronger-than-expected results for the second quarter. Warning! GuruFocus has detected 11 Warning Signs with TXN. The chipmaker reported Q2 revenue of $4.45 billion, topping the $4.36 billion analyst consensus, and earnings per share of $1.41, also ahead of the expected $1.35. Net income rose 15% year over year to $1.3 billion. Analog chip revenue, the company's core segment, climbed 18% to $3.5 billion, exceeding projections. The growth was driven by demand from the automotive and industrial markets. However, Texas Instruments guided Q3 revenue in the range of $4.45 billion to $4.8 billion, with a midpoint slightly below the $4.59 billion consensus. The company also forecast EPS between $1.36 and $1.60, bracketing analysts' $1.50 average. Shares had been up 15% year to date before the report, helped by broader enthusiasm in the semiconductor sector. The company recently committed $60 billion toward U.S. chip factory expansion, a plan supported by the Trump administration's domestic tech push. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data